AXNX:NSD-Axonics Modulation Technologies Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 67.69

Change

+0.24 (+0.36)%

Market Cap

USD 3.44B

Volume

0.23M

Analyst Target

USD 52.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.44 (-0.61%)

USD 29.04B
PODD Insulet Corporation

-1.79 (-0.77%)

USD 16.66B
BRKR Bruker Corporation

+0.46 (+0.79%)

USD 9.04B
MASI Masimo Corporation

+1.84 (+1.30%)

USD 7.53B
TMDX TransMedics Group Inc

-6.58 (-7.44%)

USD 4.17B
PRCT Procept Biorobotics Corp

-3.66 (-3.79%)

USD 3.50B
LIVN LivaNova PLC

-1.63 (-3.08%)

USD 2.90B
QDEL Quidel Corporation

+0.62 (+1.62%)

USD 2.67B
NARI Inari Medical Inc

-2.08 (-4.23%)

USD 2.57B
IRTC iRhythm Technologies Inc

-1.23 (-1.60%)

USD 2.36B

ETFs Containing AXNX

MARB First Trust Vivaldi Merge.. 4.14 % 0.00 %

+0.09 (+-0.05%)

USD 0.03B
IBRN iShares Trust - iShares N.. 3.63 % 0.00 %

-0.01 (-0.05%)

USD 4.08M
EVNT AltShares Event-Driven ET.. 2.98 % 0.00 %

-0.01 (-0.05%)

USD 4.89M
ARB AltShares Trust - AltShar.. 0.00 % 0.00 %

+0.01 (+-0.05%)

USD 0.07B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.77% 74% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.77% 74% C 70% C-
Trailing 12 Months  
Capital Gain 29.35% 82% B 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.35% 82% B 78% C+
Trailing 5 Years  
Capital Gain 123.84% 89% A- 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 123.84% 89% A- 85% B
Average Annual (5 Year Horizon)  
Capital Gain 24.14% 72% C 82% B
Dividend Return 24.14% 71% C- 82% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.58% 73% C 44% F
Risk Adjusted Return 59.50% 95% A 86% B+
Market Capitalization 3.44B 95% A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.